Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma

Neuro-Oncology

Volumn 16, Issue 6, 2014, Pages 880-888

  Schmainda, Kathleen M ^a   Prah, Melissa ^a   Connelly, Jennifer ^a   Rand, Scott D ^a   Hoffman, Raymond G ^a   Mueller, Wade ^a   Malkin, Mark G ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

bevacizumab; brain tumor; DSC; MRI; perfus; rCBV

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM TEXAPHYRIN; TAMOXIFEN; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; MONOCLONAL ANTIBODY;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BRAIN BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RELATIVE CEREBRAL BLOOD VOLUME; REOPERATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME; AGED; BRAIN CORTEX; BRAIN NEOPLASMS; IMAGE PROCESSING; MIDDLE AGED; PROCEDURES; PROGNOSIS; SURVIVAL; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CEREBRAL CORTEX; CONTRAST MEDIA; FEMALE; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84901024226     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not216     Document Type: Article

References (37)

1. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncol. 2010;12(3):233-242.
2. Moen MD. Bevacizumab in previously treated glioblastoma. Drugs. 2010;70(2):181-189.
3. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
5. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
6. Macdonald DR, Cascino TL, Schold SC, Calmcross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
7. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
8. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol. 2008;29(3):419-424.
9. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1): 83-95.
10. Rosen BR, BelliveauJW,VeveaJM, BradyTJ. Perfusionimaging withNMR contrast agents. Magn Reson Med Sci. 1990;14(2):249-265.
11. Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology. 1993;189(1):233-238.
12. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology. 1994;191(1):41-51.
13. Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol. 1996;17(5):831-840.
14. Donahue KM, Krouwer HGJ, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med Sci. 2000;43(6):845-853.
15. Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res. 2000;6(6): 2189-2200.
16. Sugahara T, Korogi Y, Kochi M, Ushio Y, Takahashi M. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol. 2001;22(7):1306-1315.
17. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology. 2006;238(2): 658-667.
18. SugaharaT, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhancedMRimaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol. 2000;21(5): 901-909.
19. Hu L, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2009;30(3):552-558.
20. Kong DS, Kim ST, Kim EH, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol. 2011;32(2): 382-387.
21. Schmainda KM, Bedekar D, Rand SD, et al. DSC-MRI measures of rCBV predict response to bevacizumab treatment more reliably than standard MRI in patients with recurrent high-grade gliomas. Paper presented at the 17th Scientific Meeting & Exhibition of the International Society International Society for Magnetic Resonance in Medicine; April 2009; Honolulu, HI.
22. SchmaindaKM,RandSD, JosephAM, etal.Characterizationofafirst-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR AmJ Neuroradiol. 2004;25(9):1524-1532.
23. Boxerman J, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade whereas uncorrected maps do not. AJNR Am J Neuroradiol. 2006;27(4):859-867.
24. Bedekar D, Jensen TR, Schmainda KM. Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter and intra-patient comparisons. Magn Reson Med Sci. 2010;64(3):907-913.
25. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5(2):143-156.
26. Jenkinson M, Bannister PR, Brady JM, Smith SM. Improved optimisation for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17(2):825-841.
27. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res. 1996;29(3): 162-173.
28. Bedekar D, Jensen T, Rand S, Malkin MG, Connelly J, Schmainda KM. Delta T1 Method: An automatic post-contrast RO1 selection technique for brain tumors. Paper presented at:the 2010 Joint Annual Meeting of the International Society for Magnetic Resonance in Medicine. European Society for Magnetic Resonance in Medicine and Biology; May 2010; Stockholm, Sweden.
29. Bedekar D, Jensen TR, Rand SD, et al. Delta T1 Method: An automatic post-contrast ROI selection technique for brain tumors. Paper presented at the 18th Scientific Meeting & Exhibition of the International Society of Magnetic Resonance in Medicine; May 2010; Stockholm, Sweden.
30. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173-180.
31. Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol. 2004; 27(1):33-38.
32. Nagy JA, Dvorak HF. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis. 2012;29(7):657-662.
33. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist. 2004;9(Suppl 1):36-42.
34. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009;15(3):167-170.
35. Ellingson BM, Rand SD, Malkin MG, Schmainda KM. Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J Neurooncol. 2010;97(3):419-423.
36. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538-548.
37. Ellingson BM, Malkin MG, Rand SD, et al. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2011;102(1):95-103.